Dr. Ali Fleury, MD
Claim this profileNH Oncology - Hematology, PA
Studies Multiple Myeloma
Studies Non-Hodgkin's Lymphoma
2 reported clinical trials
22 drugs studied
Area of expertise
1Multiple Myeloma
Stage III
Stage IV
2Non-Hodgkin's Lymphoma
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Ali Fleury, MD is currently running
T-DM1 vs TH
for Breast Cancer
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Recruiting1 award Phase 2
Targeted Therapy
for Advanced Stage Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
Recruiting1 award Phase 29 criteria
More about Ali Fleury, MD
Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ali Fleury, MD has experience with
- Abemaciclib
- Afatinib
- Atezolizumab And PHESGO
- Atezolizumab And Talazoparib
- Crizotinib
- Entrectinib
Breakdown of trials Ali Fleury, MD has run
Multiple Myeloma
Non-Hodgkin's Lymphoma
Solid Tumors
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ali Fleury, MD specialize in?
Ali Fleury, MD focuses on Multiple Myeloma and Non-Hodgkin's Lymphoma. In particular, much of their work with Multiple Myeloma has involved Stage III patients, or patients who are Stage IV.
Is Ali Fleury, MD currently recruiting for clinical trials?
Yes, Ali Fleury, MD is currently recruiting for 2 clinical trials in Concord New Hampshire. If you're interested in participating, you should apply.
Are there any treatments that Ali Fleury, MD has studied deeply?
Yes, Ali Fleury, MD has studied treatments such as Abemaciclib, Afatinib, Atezolizumab and PHESGO.
What is the best way to schedule an appointment with Ali Fleury, MD?
Apply for one of the trials that Ali Fleury, MD is conducting.
What is the office address of Ali Fleury, MD?
The office of Ali Fleury, MD is located at: NH Oncology - Hematology, PA, Concord, New Hampshire 03103 United States. This is the address for their practice at the NH Oncology - Hematology, PA.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.